The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.
The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.
HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).
On This Page
- All Heading 2s will automatically be pulled in to this list.
- Do not edit the content on this template.
About Pre-Cancer Atlas
The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.
PCA Research Centers have three major tasks:
- Collecting, processing, and labeling biospecimens.
- Studying the molecular, cellular, and spatial details of the lesions.
- Analyzing and modeling the data.
PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.
Grantee Details
| PI Name Sort descending | PI Organization | Title | Grant Number | Program Official |
|---|---|---|---|---|
| Zhu, Yazhen | University Of California Los Angeles |
Extracellular Vesicle-Based Digital Scoring Assay for Detecting Early-stage Hepatocellular Carcinoma | 5R01CA255727-05 | Matthew Young, Ph.D. |
| Zhu, Yong | Univ Of Arkansas For Med Scis |
Explore piRNAs as a novel group of biomarkers for ovarian cancer early detection | 1R21CA277412-01A1 | Christos Patriotis, Ph.D., M.Sc. |
| Zi, Xiaolin | University Of California-Irvine |
Nautral products for targeting Skp2 in cancer interception | 5UG3CA290368-02 | Altaf Mohammed, Ph.D. |
Pagination
- First page
- Previous page
- …
- 53
- 54
- 55
- 56